SCHEMBL6932901

SCHEMBL6932901

O=C1OC(c2ccccc2)(c2ccc(-c3ccc(Cl)cc3)cc2Cl)C(O)=C1O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PGR P06401 2/20 0.41
ESR2 Q92731 2/20 0.38
MAP3K14 Q99558 1/20 0.37
HSP90AA1 P07900 2/20 0.36
FTO Q9C0B1 1/20 0.36
CFTR P13569 1/20 0.36
GOPC Q9HD26 1/20 0.36
TYMS P04818 2/20 0.36
DHFR P00374 1/20 0.36
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
OPRM1 P35372 1/20 0.35
OPRD1 P41143 1/20 0.35
CYP1A2 P05177 1/20 0.34
AKR1C2 P52895 1/20 0.34
AKR1C1 Q04828 1/20 0.34
HCAR2 Q8TDS4 2/20 0.33
HCAR3 P49019 1/20 0.33
ALOX5 P09917 1/20 0.33
ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6934449 0.90 AKR1C2 (0.41) PGRESR2HSP90AA1FTOCFTR
SCHEMBL7586371 0.90 AKR1C2 (0.41) PGRESR2HSP90AA1FTOCFTR
SCHEMBL6932670 0.85 MDM2 (0.38) MEN1KMT2AALDH1A1MAPTSMN1; SMN2
SCHEMBL7966642 0.85 CYP1A2 (0.41) ESR2HSP90AA1CFTRGOPCTYMS
SCHEMBL6931685 0.78 PGR (0.43) PGRESR2FTOHCAR2HCAR3
SCHEMBL7956300 0.78 LMNA (0.43) ESR2HSP90AA1CFTRGOPCTYMS
SCHEMBL6932932 0.77 MDM2 (0.38) KMT2AAKR1C2AKR1C1ALDH1A1MAPT
SCHEMBL6932601 0.76 CFTR (0.43) ESR2HSP90AA1CFTRGOPCTYMS
SCHEMBL6026158 0.74 CFTR (0.50) ESR2HSP90AA1CFTRGOPCTYMS
SCHEMBL7967152 0.73 PGR (0.38) PGRHSP90AA1CFTRGOPCDHFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6265436-B1 ANTIINFLAMMATORY AGENTS OXIS THERAPEUTICS INC. 2001-07-24 US claimed
EP-1246811-B1 METHODS FOR RESOLVING RACEMIC MIXTURES OF 5-SUBSTITUTED 4-HYDROXY-2-FURANONES OXIS ISLE OF MAN LTD (GB) 2003-12-03 EP disclosed
US-6613919-B2 Resolution with enantiomerically pure bases such as cinchonidine by forming a salt; also 3,4-dihydroxy-2(5H)-furanones OXIS ISLE OF MAN 2003-09-02 US disclosed
US-20030065196-A1 Method for resolving racemic mixtures of 5-substituted 4-hydroxy-2-furanones OXIS ISLE OF MAN 2003-04-03 US disclosed
EP-1246811-A1 METHODS FOR RESOLVING RACEMIC MIXTURES OF 5-SUBSTITUTED 4-HYDROXY-2-FURANONES OXIS Isle of Man, Limited (GB) 2002-10-09 EP disclosed
US-6265436-B1 ANTIINFLAMMATORY AGENTS OXIS THERAPEUTICS INC. 2001-07-24 US disclosed
WO-2001049671-A1 METHODS FOR RESOLVING RACEMIC MIXTURES OF 5-SUBSTITUTED 4-HYDROXY-2-FURANONES OXIS ISLE OF MAN, LIMITED (US) 2001-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030065196-A1 Method for resolving racemic mixtures of 5-substituted 4-hydroxy-2-furanones ADH1C, SRD5A2, SRD5A1 PGR 3900/4885ESR2 3583/4885MAP3K14 4694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.